Telecom gear maker Huawei India decides to set up a 50-bed covid-19 medical care facility in Gurugram in partnership with a local medical institution. Besides this, the company is also facilitating the availability of 400 oxygen concentrators, 400 contactless vital parameter monitoring devices, 25 HFNC CPAP oxygen therapy system and other medical services worth INR 5 crore for various public hospitals, makeshifts hospitals and other essential facilities of COVID19.
Understanding the urgency and the demand of the healthcare requirements firm had decided to join hands with the local partners to boost up the facilitation of the urgent medical supplies to support those who are most affected and are in high need of medical supplies. This partnership will help them to reach the local areas and get the data of people with the need in underprivileged areas.
Huawei has also collaborated with various NGOs and specialized institution to facilitate the medical resources to strengthen the management power in the crises of covid19. Huawei India has also set up an emergency team to cater for emergency medical needs and to provide hospitalization support to their employees and all other people depending upon them.
Founded in 1987, Huawei is the global leading provider of information and communications technology infrastructure and smart devices. Huawei is a private company fully owned and managed by its employees. They have around 197000 employees with an operating range of around 170 countries serving more than three billion people around the world. No government agency or outside organization holds shares in Huawei.
David Li, CEO of Huawei India said, “We firmly believe that this situation can be overcome with the joint, comprehensive and community efforts. We at Huawei are committed to stand strong with the nation during these hard times of the nation”. The company also said that they will be contributing to meal support for more than 18000 government school children whose families are greatly affected in the covid19.
The Hyderabad based firm Bharat Biotech technology on Thursday had declared that they plan to produce additional 200 million doses of COVID19 vaccine ‘covaxin’ at its subsidiary’s Ankleshwar (Gujarat) based facility, with an average production of 1 billion dosages per annum.